NYMC Faculty Publications
BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review
Author Type(s)
Resident/Fellow, Faculty
DOI
10.3390/jcm13010113
Journal Title
Journal of Clinical Medicine
Document Type
Article
Publication Date
12-25-2023
Department
Medicine
Abstract
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths globally. BRAF mutation is present in about 10% of CRC patients and is associated with a poor response to chemotherapy. These patients have a relatively poor prognosis. This review aims to assess the efficacy and safety of BRAF inhibitors in BRAF-mutated CRC patients. A literature search was performed on PubMed and Embase, and clinical trials relevant to BRAF inhibitors in CRC were included. Data were extracted for efficacy and safety variables. Two randomized clinical trials (n = 765) and eight non-randomized trials (n = 281) were included based on inclusion criteria. In RCTs, an overall response was reported in 23% of the patients treated with BRAF inhibitor-based regimens compared to 2.5% with control regimens. The hazard ratio of overall survival was also significantly better with triplet encorafenib therapy at 0.52 (95% CI = 0.39-0.70). In single-arm trials, ORR was 17% and 34% in two-drug and three-drug regimens, respectively. BRAF inhibitor-based regimens were safe and effective in the treatment of BRAF-mutated CRC. Large-scale randomized trials are needed to find a suitable population for each regimen. PROSPERO registration No. CRD42023471627.
Recommended Citation
Aiman, W., Ali, M. A., Jumean, S., Asfeen, U., Garcia, J., Quirem, M., Ahmad, A., Rayad, M. N., Alkhlaifat, O., Al Omour, B., Chemarthi, V. S., Maroules, M., Guron, G., & Shaaban, H. (2023). BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review. Journal of Clinical Medicine, 13 (1). https://doi.org/10.3390/jcm13010113